ZINC000443438219 (Compound 8219) is a highly potent, selective and non-competitive inhibitor of serotonin transporter (SERT) with Ki of 3 nM.

ABT-418 hydrochloride (ABT418) is an analog of (-)-nicotine and cholinergic ligand (activator) of nAChRs, a potent inhibitor of [3H]-cytisine binding to nAChR in rat brain with Ki of 2 nM.

Tebanicline dihydrochloride (ABT-594) is a potent, orally active neuronal nicotinic acetylcholine receptor (alpha 4 beta 2 nAChR) agonist with Ki of 37 pM (rat brain) and 55 pM (transfected human receptor).

AN317 is a functionally selective, partial agonist of α6β2-containing nicotinic acetylcholine receptor (nAChR) with pEC50 of 7.17 (α6/α3β2β3V9'S receptor) in cell-based assays, inhibits the effect of nicotine with IC50 of 1.1 uM.

AT1001 (AT-1001) is a high affinity and selective α3β4 nAChR antagonist with Ki value of 2.4 nM, >90-fold selectivity over the other major subtypes (α4β2 and α7 nAChR).

Cris-104 is a selective α4β2* neuronal nAChR agonist, demonstrates antinociceptive and antihypersensitivity in rodent acute/inflammatory and chronic pain models.

CVN417 (CVN-417) is a potent, selective and brain-penetrant α6-containing nicotinic acetylcholine receptor (α6 nAChR) antagonist with Ca2+ flux IC50 of 86 nM.

DM506 is a novel ibogamine derivative and inhibitor of α7 and α9α10 nicotinic acetylcholine receptors (nAChRs) with IC50 of 5.1 uM, 5.6 uM and 6.4 uM for α9α10, α7β2 and α7nAChR, respectively.

JWX-A0108 is a novel selective type I α7 nAChR positive allosteric modulator (PAM) with EC50 of 4.35 uM, shows no potentiation effect on α3β4 nAChR, α4β2 nAChR, or 5-HT3AR.

MK4334 is a potent, selective positive allosteric modulator (PAM) of the α7 nAChR with potential for treatment of Alzheimer's disease.

RGH-560 (RGH560) is a potent, selective α7 nAChR positive allosteric modulator (PAM) with EC50 of 190 nM (Ca2+-influx).

DT-0111 (DT0111) is a selective and effective, water-soluble antagonist at P2X2/3R, does not activate or block P2YR, inhibits ATP-induced current in nodose ganglionic cells with IC50 of 0.3 uM.

Filapixant (BAY1902607) is a potent, selective P2X3 receptor antagonist, shows a substantially higher in vitro selectivity for P2X3 over P2X2 when compared with Eliapixant (BAY1817080, Cat# PC-72754).

3hi2one-G4 is a highly selective small molecule activator targeting GIRK4 homomeric channels, does not activate GIRK2, GIRK1/2 or GIRK1/4 channels.

ACOU001 (ACOU 001) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with potential effect against ge-related hearing loss (ARHL) and other hearing impairments related to compromised KV7.4 function.

ACOU085 (ACOU 085) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with higher potency than ML-213 in the nanomolar range.

AUT00201 is a potent, selective Kv3 potassium channel modulator with potential for the treatment of rare epilepsy syndromes.

BK channel modulator BC5 is an allosteric modulator of BK type Ca2+-activated K+ channels, interacts with the CTD-VSD interface and specifically modulates the Ca2+ dependent activation mechanism.

C101248 is the first selective small-molecule inhibitor of tandem pore domain halothane-inhibited K+ channel 1 (THIK-1) with IC50 of 50 nM for both mouse and human THIK-1.

KCNQ2 activator Ebio1 is a potent and subtype-selective activator for the voltage-gated potassium channel KCNQ2 (Kv7.2) with EC50 of 247.3 nM, directly opens the KCNQ2 channel.

LAKI (Light Activated K+ channel Inhibitor) is a specific photoswitchable inhibitor of the pain-related two-pore-domain potassium (K2P) TREK and TRESK channels.

ML308 (ML 308) is a potent, selective inhibitor of two-pore domain potassium channel KCNK9 (TASK-3, K2P9.1) with IC50 of 130 nM in thallium influx fluorescent assays and 413 nM in automated electrophysiology assays, respectively.